Coming back to: Renal impairment: what the labelling says about dose posts 31–35

Confirming post #30 from a second method, which matters more than confirming it from a second person.

Hypoglycemia risk: in people already on insulin or sulfonylureas, adding a GLP-1 agonist requires insulin dose reduction and close monitoring for hypoglycemia. This is manageable with attention.

I keep a log of this specifically because memory is unreliable about it.

I had written a reply contradicting post #28 and deleted it. Here is what survived.

Second-hand on Renal impairment, so weight it accordingly — someone whose method I trust told me this and I have not verified it myself.

The bit of Renal impairment that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.

The most useful contribution here is usually a citation to whichever published document comes closest, with a plain statement of how far it is from the question.

My position on Renal impairment is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.